Last reviewed · How we verify
PF-06817024
PF-06817024 is a Biologic drug developed by Pfizer. It is currently in Phase 1 development.
At a glance
| Generic name | PF-06817024 |
|---|---|
| Sponsor | Pfizer |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Upper respiratory tract infection
- Pain in extremity
- Ecchymosis
- Diarrhoea
- Chest pain
- Infusion site pain
- Infusion site reaction
- Skin laceration
- Libido increased
- Acne
- Dermatitis atopic
- Erythema
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-06817024 CI brief — competitive landscape report
- PF-06817024 updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about PF-06817024
What is PF-06817024?
PF-06817024 is a Biologic drug developed by Pfizer.
Who makes PF-06817024?
PF-06817024 is developed by Pfizer (see full Pfizer pipeline at /company/pfizer).
What development phase is PF-06817024 in?
PF-06817024 is in Phase 1.
What are the side effects of PF-06817024?
Common side effects of PF-06817024 include Upper respiratory tract infection, Pain in extremity, Ecchymosis, Diarrhoea, Chest pain, Infusion site pain.
Related
- Manufacturer: Pfizer — full pipeline
- Compare: PF-06817024 vs similar drugs
- Pricing: PF-06817024 cost, discount & access